/
Relapsed/Refractory Follicular Lymphoma Conundrums Relapsed/Refractory Follicular Lymphoma Conundrums

Relapsed/Refractory Follicular Lymphoma Conundrums - PowerPoint Presentation

danika-pritchard
danika-pritchard . @danika-pritchard
Follow
354 views
Uploaded On 2018-11-06

Relapsed/Refractory Follicular Lymphoma Conundrums - PPT Presentation

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 717482

agents trial chronos magnify trial agents magnify chronos idelalisib copanlisib therapies gadolin treatment safety recommended lenalidomide selecting duvelisib therapy

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Relapsed/Refractory Follicular Lymphoma ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Relapsed/Refractory Follicular Lymphoma ConundrumsSlide2

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3

Epidemiology of FLSlide4

Presentation TopicsSlide5

Recommended Frontline Therapies for FLSlide6

Considerations in Selecting Therapy for R/R FLSlide7

Recommended Second-Line Therapies for FLSlide8

Management Challenges in R/R FLSlide9

Strategies for Selecting Therapy for R/R FLSlide10

Novel TherapiesSlide11

Copanlisib Slide12

CHRONOS-1 Trial of Copanlisib

Methods Slide13

CHRONOS-1 Trial of CopanlisibEfficacySlide14

CHRONOS-1 Trial of Copanlisib

SafetySlide15

Idelalisib Slide16

Phase 2 Trial of Idelalisib Monotherapy in R/R FL

Design and Efficacy Slide17

Phase 2 Trial of Idelalisib Monotherapy in R/R FL

Safety Slide18

DuvelisibSlide19

DYNAMO Trial of DuvelisibSlide20

MAGNIFY Trial of Rituximab + Lenalidomide Design

Slide21

MAGNIFY TrialResponseSlide22

MAGNIFY TrialPFSSlide23

MAGNIFY TrialSafetySlide24

Additional Trials of R + LenalidomideSlide25

Obinutuzumab Slide26

GADOLIN TrialDesignSlide27

GADOLIN Trial

EfficacySlide28

GADOLIN TrialSafetySlide29

Incorporating New Agents Into Treatment Paradigm

ChallengesSlide30

Incorporating New Agents Into Treatment Paradigm

SelectionSlide31

Current Knowledge About Novel AgentsSlide32

Ongoing Trials in R/R FLSlide33

AbbreviationsSlide34

Abbreviations (cont)